Lupin: Fundamental Radar: Why risk-reward in Lupin remains f

The company’s US business was adversely impacted by regulatory issues. However, with clearance for the formulation sites, the product pipeline could continue to unfold over the next 3-4 years for the drugmaker.

Related Keywords

Mumbai , Maharashtra , India , , Lupin Ltd , Pharma , Lupin , Company , Business , Apis ,